COCP Cocrystal Pharma, Inc.
Company Updates ·
Cocrystal Pharma said on September 9, 2026 that it dosed the last subject in its Phase 1b norovirus challenge study of CDI-988, with preliminary efficacy results expected in late 2026 or early 2027.
Cocrystal Pharma's board appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately, according to a Form 8-K filed August 18, 2026.
OPKO Health, a longtime shareholder, buys 5,474,053 shares at $0.9134 each in a private placement with no warrants attached.
An 8-K filed June 9, 2026 sets out the offer letter for the new chief executive, who replaces two co-chief executives.
The antiviral developer names a former biopharma chief executive with 23 product launches to lead the company, effective immediately.
The company says its novel direct-acting antivirals show pan-viral activity in early in vitro work against hantavirus, bunyavirus and influenza.
The company says the first cohort of its Phase 1b norovirus challenge study is fully enrolled, with prevention and treatment cohorts to follow.
The oral antiviral candidate gains earlier FDA contact and a possible path to Priority Review, Cocrystal said in an April 2, 2026 release.
The company agreed to sell 2,764,710 shares at $1.70 each, with warrants for up to 5,529,420 shares at $1.50 that could add approximately $8.3 million if fully exercised for cash. H.C. Wainwright & Co. is the placement agent.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. Its small molecule candidates inhibit the viral replication function of RNA viruses, including influenza virus, norovirus, coronaviruses (including SARS-CoV-2 and MERS-CoV), respiratory virus infections and hepatitis C virus (HCV) infections. The company uses a proprietary structure-based platform that combines computational chemistry, medicinal chemistry and X-ray crystallography. It determines the structures of cocrystals containing inhibitors bound to viral enzymes to guide drug design, and it aims for broad-spectrum candidates with a high barrier to viral resistance. Its approach was developed under the guidance of Dr. Roger Kornberg, the company's Chief Scientist and Chairman of its Scientific Advisory Board and Board of Directors, who received the Nobel Prize in Chemistry in 2006. The company describes its portfolio as including discovery, preclinical and clinical stage antiviral compounds, and it states that it operates as one business entity.
| Product or program | What it is | Stage |
|---|---|---|
| Influenza virus antivirals | Direct-acting antivirals targeting influenza viral replication enzymes | discovery, preclinical and clinical stages (portfolio-wide) |
| Norovirus antivirals | Direct-acting antivirals targeting norovirus replication | discovery, preclinical and clinical stages (portfolio-wide) |
| Coronavirus antivirals | Antivirals for SARS-CoV-2 and MERS-CoV | discovery, preclinical and clinical stages (portfolio-wide) |
| Hepatitis C antivirals | Antivirals for hepatitis C virus infection | discovery, preclinical and clinical stages (portfolio-wide) |
| Respiratory virus antivirals | Antivirals for respiratory virus infections | discovery, preclinical and clinical stages (portfolio-wide) |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $5.1 million | $12.5 million |
| Net income (loss) | -$8.8 million | -$17.5 million |
| Cash from operations | -$8.2 million | -$16.5 million |
| Cash and equivalents | $7.0 million | $9.9 million |
Our latest story on this, dated Aug 3, 2026: "Cocrystal sells $5 million of stock to OPKO Health". The story links the filing or release it is based on. Read the story.
Cocrystal Pharma, Inc. trades under the ticker COCP on NASDAQ.
Cocrystal Pharma, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:8CC; LS:A3DWYX.
The SEC Central Index Key (CIK) for Cocrystal Pharma, Inc. is 1412486. Its filings are on SEC EDGAR.
19,263,200 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Cocrystal Pharma, Inc. under United States.
Our directory classifies Cocrystal Pharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cocrystal Pharma, Inc. is US19188J4094.
aibio.space lists Cocrystal Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. Its small molecule candidates inhibit the viral replication function of RNA viruses, including influenza virus, norovirus, coronaviruses (including SARS-CoV-2 and MERS-CoV), respiratory virus infections and hepatitis C virus (HCV) infections.
Influenza virus antivirals: Direct-acting antivirals targeting influenza viral replication enzymes Stage: discovery, preclinical and clinical stages (portfolio-wide).
Norovirus antivirals: Direct-acting antivirals targeting norovirus replication Stage: discovery, preclinical and clinical stages (portfolio-wide).
Cocrystal Pharma, Inc. reported a net loss of $8.8 million for the fiscal year ended Dec 31, 2025, and used $8.2 million of cash in operations, per its annual report to the SEC.
$5.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio